ADVERTISEMENT
Pemigatinib for Locally Advanced or Metastatic Cholangiocarcinoma: FIGHT-202 Trial
Recorded at the 2022 ESMO World Congress on Gastrointestinal Cancer, this video features Prof Arndt Vogel, MD, Medizinische Hochschule Hannover, Germany, and Prof Michel Ducreux, MD, PhD, Gustave Roussy, Paris, France, discussing the final results from the phase 2, FIGHT-202 trial.
The FIGHT-202 trial evaluated the efficacy and safety of pemigatinib, a selective inhibitor of fibroblast growth factor receptor (FGFR), in patients with previously treated, locally advanced or metastatic cholangiocarcinoma. In this video, Professor Vogel focuses on the final efficacy and safety results for patients with confirmed FGFR2 fusions/rearrangements.
Disclaimer:
This video contains the independent opinion of expert physicians discussing data presented during ESMO World Congress on Gastrointestinal Cancer (29 June – 2 July 2022; Barcelona, Spain). The oral presentation ‘Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202’ (oral presentation reference: O-2), discussed in this video was originally presented by Professor Arndt Vogel on 29 June 2022. Reference: Vogel A, et al. Ann Oncol. 2022;33(suppl 4): S379. Please note this video contains information on Pemazyre which received EMA approval on 26 March 2021 but is not currently reimbursed in all EU countries yet. The viewer should take the necessary precautions to adhere to regulations and guidance set by their local governing healthcare authority and to review the Product Information inclusive of the Summary of Product Characteristics if considering Pemazyre.
